References
- Stewart WF, Schechter A, Lipton RB. Migraine heterogeneity, disability, pain intensity and attack frequency and duration. Neurology 44(Suppl. 4), S24–S39 (1994).
- Rasmussen BK. Epidemiology of headache. Cephalalgia 15, 45–68 (1995).
- Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders. Second Edition. Cephalalgia 24(Suppl. 1), 1–160 (1994).
- Stewart WF, Lipton RB, Simon D. Work-related disability: results from the American migraine study. Cephalalgia 16, 231–238 (1996).
- Lipton RB, Stewart WF. Prevalence and impact of migraine. Neurol. Clin. 15, 1–13 (1997).
- Tfelt-Hansen P, Welch KMA. General principles of pharmacological treatment of migraine. In: The Headaches. Second Edition. Olesen J, Tfelt-Hansen P, Welch KMA (Eds). Lippincott Willians & Wilkins, PA, USA, 385–389 (2000).
- Silberstein SD, Saper JR, Freitag FG. Migraine: diagnosis and treatment. In: Wolff’s Headache and Other Head Pain. Seventh Edition. Silberstein SD, Lipton RB, Dalessio DJ (Eds). Oxford University Press, NY, USA, 121–246 (2001).
- Krymchantowski AV, Bigal ME, Moreira PF. New and emerging prophylactic agents for migraine. CNS Drugs 16(9), 611–634 (2002).
- Pascual J, Leira R, Lainez JM. Combined therapy for migraine prevention? Clinical experience with a β-blocker plus sodium valproate in 52 resistant migraine patients. Cephalalgia 23, 961–962 (2003).
- Krymchantowski AV, Hampshire F. Polytherapy in migraine prevention. Clinical experience with the combination of a β-blocker plus a tricyclic antidepressant plus a calcium channel blocker. Headache 44, 499–500 (2004).
- Shachter SC. Epilepsy. Neurol. Clin. 19, 57–78 (2001).
- Young WB, Siow HC, Silberstein SD. Anticonvulsants in migraine. Curr. Pain Headache Rep. 8(3), 244–250 (2004).
- Krymchantowski AV, Tavares C. Weight variations in patients receiving topiramate migraine prophylaxis in a tertiary care setting. Med. Gen. Med. 6(3), 48 (2004).
- Dodick DW. Acute and prophylactic management of migraine. Clin. Cornerstone 4, 36–52 (2001).
- Goadsby PJ, Lipton RB, Ferrari MD. Migraine – current understanding and treatment. N. Engl. J. Med. 346, 257–270 (2002).
- Lipton RB, Stewart WF, Cady R et al. 2000 Wolff Award. Sumatriptan for the range of headaches in migraine sufferers: results of the Spectrum Study. Headache 40, 783–791 (2000).
- Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? Headache 42(Suppl. 1), 3–9 (2002).
- Saxena P, Tfelt-Hansen P. Triptans, 5-HT1B/1D receptor agonists in the acute treatment of migraine. In: The Headaches. Second Edition. Olesen J, Tfelt-Hansen P, Welch KMA (Eds). Lippincott Williams & Wilkins, PA, USA, 411–438 (2000).
- Peroutka SJ. Beyond monotherapy: rational polytherapy in migraine. Headache 38, 18–22 (1998).
- Bates D, Ashford E, Dawson R et al. Subcutaneous sumatriptan during the migraine aura. Neurology 44, 1587–1592 (1994).
- Visser WH, de Vriend RH, Jaspers NHWM, Ferrari MD. Sumatriptan – nonresponders: a survey in 366 migraine patients. Headache 36, 471–475 (1996).
- Dahlof CG. How does sumatriptan perform in clinical practice? Cephalalgia 15(Suppl. 15), 21–28 (1995).
- Visser WH, de Vriend RH, Jaspers NHWM, Ferrari MD. Sumatriptan in clinical practice: a 2-year review of 453 migraine patients. Neurology 47, 46–51 (1996).
- Krymchantowski AV. Acute treatment of migraine. Breaking the paradigm of monotherapy. BMC Neurol. 28(4), 1–4 (2004).
- Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain 89(2–3), 107–110 (2001).
- Lance JW. Headache. Ann. Neurol. 10, 1–10 (1981).
- Wilkinson M. treatment of the acute migraine attack – current status. Cephalalgia 3, 61–67 (1983).
- Callahan M, Raskin N. A controlled study of dihydroergotamine in the treatment of acute migraine headache. Headache 26, 168–171 (1986).
- Krymchantowski AV, Adriano M, Fernandes D. Tolfenamic acid decreases migraine recurrence when used with sumatriptan. Cephalalgia 19, 186–187 (1999).
- Krymchantowski AV. Naproxen sodium decreases migraine recurrence when administered with sumatriptan. Arq. Neuropsiquiatr. 58(2-B), 428–430 (2000).
- Krymchantowski AV, Barbosa JS. Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. Cephalalgia 22, 309–312 (2002).
- Krymchantowski AV, Bigal ME. Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine. BMC Neurol. 4(1), 10 (2004).